Skip to content

Author

A. Anbarasu

We have 9 of 215 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Biofilm-driven antimicrobial resistance: A review of molecular mechanisms, clinical implications, and therapeutic innovation.

This review provides an integrated overview of the molecular and genetic determinants governing biofilm development, including surface attachment, matrix biosynthesis, quorum-sensing networks, cyclic-di-GMP signaling, maturation, and dispersal.

T. Chakraborty, Madhuchhanda Chatterjee, Sayanika Das et al. · 0 citations
Review Open access Sep 2026

Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders

This review was developed following a structured literature search of major biomedical databases and clinical trial registries to synthesize current evidence on the therapeutic applications of CRISPR-Cas9 in oncology and inherited genetic disorders.

Khushi Bashir, Prathiksha Vasudev, Vikas Chhetri et al. · 0 citations
Review Open access Aug 2026

An overview of bioinformatics approaches to understand drug resistance and identifying novel inhibitors against multidrug-resistant Mycobacterium tuberculosis

This review underscores the critical role of bioinformatics in addressing the global burden of MDR-TB and highlights its transformative role in guiding next-generation anti-TB drug development.

Elizabeth Annie George, Mahima Senthilkumar, Kavitha Thirupugazh et al. · 0 citations
Aug 2026

In Silico Analysis of an Antidiabetic Drug Canagliflozin as a Potential Inhibitor of Penicillin‐Binding Protein 3 in Acinetobacter baumannii

Canagliflozin is suggested as a potent PBP3‐binding drug against the A. baumannii pathogen, which stands as a critical priority pathogen, rapidly developing resistance against the currently available antibiotic treatments, including last‐resort antibiotics.

Srujal Kacha, A. Anbarasu · 0 citations
Open access Aug 2026

Comparative genomics of carbapenem resistant and susceptible clinical Acinetobacter baumannii reveals lineage-associated mobilization of acquired carbapenemase determinants: an integrative in silico genomics approach

The findings underscore the complex interplay between ARGs, VFs, and MGEs in the genomic evolution of CRAB, expanding current understanding of CRAB adaptation and may contribute toward enhanced surveillance, antimicrobial stewardship, and exploration of alternative therapeutic targets.

Sara Pearl, A. Anbarasu · 0 citations
Review Open access Aug 2026

Multimodal artificial intelligence and machine learning in oncology: from data integration to precision cancer care

The role of multimodal artificial intelligence and machine learning in bridging the gap in interpreting heterogeneous modalities to improve risk prediction, prognostic assessment, and treatment decision-making in precision oncology is focused on.

Shruthi Suresh, A. Parvathy, Megha Raj et al. · 0 citations
Open access Jul 2026

An integrated subtractive genomics and immunoinformatics approach for designing a universal multi-epitope vaccine against Brucella spp.

Vc7 has been identified as a structurally stable and highly immunogenic construct, suggesting its potential as a universal multi-epitope vaccine candidate for the prevention of brucellosis.

Rhitam Biswas, Swapno Surabhi Sinha, Aditi Roy et al. · 0 citations
Review Open access Jul 2026

AI/ML-Enabled Multi-Omics Integration of Host Genetics, Immunity, and the Gut Microbiome in Crohn's Disease: From Diagnosis to Theranostics.

This review aims to assess how AI- and ML-driven multi-omics offer comprehensive insights into pathogenicity, thereby enhancing diagnostic techniques and personalized therapeutic approaches in Crohn's disease and enhancing precision healthcare delivery.

Nivedita Kedari, Urjaswee Dey, Desai Sreenija et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.